Summit Therapeutics (SMMT) Profit After Tax (QoQ) (2017 - 2026)

Summit Therapeutics (SMMT) Profit After Tax (QoQ) (2017 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Summit Therapeutics 10.29 Bn 9.60 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2026 -13.89%
Mar 31, 2026 13.51%
Dec 31, 2025 5.52%
Sep 30, 2025 59.04%
Jun 30, 2025 -799.49%
Mar 31, 2025 -2.79%
Dec 31, 2024 -8.80%
Sep 30, 2024 6.84%
Jun 30, 2024 -38.90%
Mar 31, 2024 -18.48%
Dec 31, 2023 -72.52%
Sep 30, 2023 -34.97%
Jun 30, 2023 97.09%
Mar 31, 2023 -2,878.61%
Dec 31, 2022 15.05%
Sep 30, 2022 -27.80%
Jun 30, 2022 27.58%
Mar 31, 2022 14.55%
Dec 31, 2021 -32.44%
Sep 30, 2021 16.19%